Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CLLS Relative to the S&P 500

CLLS Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Cellectis SA (NASD:CLLS) seasonal charts above shows that a Buy Date of October 18 and a Sell Date of January 6 has resulted in a geometric average return of 10.29% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 37.79% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andr Choulika on February 20, 1999 and is headquartered in Paris, France.

To download CLLS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CLLS